Clinical trial · Observational
Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
Clinical Outcomes and Quality of Life After Transarterial Radioembolization With Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI left organization and discontinued study
Summary
Brief summary (as posted)
This study will be performed to evaluate the Clinical Outcomes and Quality of Life after Transarterial Radioembolization with Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults with Liver Tumors. The treatment and techniques used here are well established in adults. The purpose of this study is to evaluate: 1. the response to treatment and clinical outcomes of treatment with TARE Y-90 as part of standard therapy and 2. to assess the change in the patient's quality of life before, during and after treatment with TARE-Y90
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatoblastoma | Hepatoblastoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Tumors | Liver Neoplasm | ALIAS | 0.90 |
| Pediatric Liver Cancer | Childhood Malignant Liver Neoplasm | ALIAS | 0.90 |
| Rhabdoid Tumor of Liver | — | UNRESOLVED | — |
| Undifferentiated (Embryonal) Sarcoma of the Liver | Undifferentiated Embryonal Sarcoma of the Liver | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of Life Assessment | Behavioral | — | UNRESOLVED |
| Transarterial Radioembolization | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Standard Treatment
- description
- Evaluation of change of HRQOL survey responses will be performed: * at baseline (time of treatment) and * 1 month post treatment * 6 months post treatment * 12 months post treatment * 5 years post-treatment The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database
- interventionNames
- Behavioral: Quality of Life Assessment
- Radiation: Transarterial Radioembolization
Primary outcomes (13)
- measure
- Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
- timeFrame
- Assessed at baseline/time of treatment
- description
- Evaluation of change of HRQOL survey responses will be performed: -at baseline (time of treatment) The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database
- measure
- Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Boys and girls age \< 21 years of age * History of liver tumor * Meet criteria for treatment with TARE-Y90 Exclusion Criteria: * • Inability to complete required study procedures.
References
Publications (1)
- RESULTAguado A, Ristagno R, Towbin AJ, Gupta A, Haberle S, Qi Z, Patel MN, Kukreja KU, Tiao GM, Geller JI. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer. 2019 Jul;66(7):e27510. doi: 10.1002/pbc.27510. Epub 2018 Nov 8. PMID 30406959